The Health Sciences Authority (HSA) has given an approval for Celgosivir as a treatment for dengue to be tested on patients in Singapore. The clinical trial, titled CELADEN (Celgosivir as a Treatment AgainstDengue), launched last week as a joint effort between Singapore General Hospital and Duke-NUS Graduate Medical School .
Pending the outcome of clinical trials, Celgosivir may become the world’s first drug to treat dengue fever. Currently, only supportive treatment is available for dengue. About 5,330 dengue cases were reported in Singapore last year, and up to 100 million people are infected annually worldwide.
More information about CELADEN clinical trial can be found at www.celaden.sg .